Akshay Parihar – författare

"e;A comprehensive exploration of the condition and the cutting-edge therapeutic options being developed for the management of cystic fibrosis . . . A quality book on cystic fibrosis management."e;-From the Foreword by Dr. Dhruv Galgotia, CEO, Galgotias University, Greater Noida, IndiaBringing together current research, therapeutic advances, and clinical perspectives, the volume offers a cohesive understanding of cystic fibrosis (CF) and the evolving strategies used to manage it. By bridging fundamental science with applied pharmaceutical innovation, this book underscores a shift toward more targeted, efficient, and patient-specific treatment strategies.The book begins with a clear overview of CF, outlining its genetic basis, clinical manifestations, and significant impact on patient health and quality of life. It then explores the underlying pathophysiology associated with CFTR mutations, emphasizing the disruptions in cellular processes that drive disease progression. Particular attention is given to microbial infections, which play a critical role in worsening symptoms, reinforcing the need for effective infection control and integrated care approaches. Building on this foundation, the volume highlights emerging and advanced therapeutic approaches. It examines the growing importance of gene therapy and personalized medicine, alongside innovations in drug delivery systems designed to enhance treatment precision and effectiveness. Technologies such as liposomes, lipid nanoparticles, and polymeric nanocarriers are presented as key enablers of targeted delivery.

"e;A comprehensive exploration of the condition and the cutting-edge therapeutic options being developed for the management of cystic fibrosis . . . A quality book on cystic fibrosis management."e;-From the Foreword by Dr. Dhruv Galgotia, CEO, Galgotias University, Greater Noida, IndiaBringing together current research, therapeutic advances, and clinical perspectives, the volume offers a cohesive understanding of cystic fibrosis (CF) and the evolving strategies used to manage it. By bridging fundamental science with applied pharmaceutical innovation, this book underscores a shift toward more targeted, efficient, and patient-specific treatment strategies.The book begins with a clear overview of CF, outlining its genetic basis, clinical manifestations, and significant impact on patient health and quality of life. It then explores the underlying pathophysiology associated with CFTR mutations, emphasizing the disruptions in cellular processes that drive disease progression. Particular attention is given to microbial infections, which play a critical role in worsening symptoms, reinforcing the need for effective infection control and integrated care approaches. Building on this foundation, the volume highlights emerging and advanced therapeutic approaches. It examines the growing importance of gene therapy and personalized medicine, alongside innovations in drug delivery systems designed to enhance treatment precision and effectiveness. Technologies such as liposomes, lipid nanoparticles, and polymeric nanocarriers are presented as key enablers of targeted delivery.